Tecan acquires IBL International to offer integrated solution for specialty diagnostics
MÄNNEDORF, SWITZERLAND – July 30, 2014. The Tecan Group (SIX Swiss Exchange: TECN) today announced the acquisition of IBL International as an important strategic step to support Tecan’s evolution into a solutions business with a higher share of recurring revenues
IBL International and Biohit sign exclusive distribution agreement for GastroPanel® immunoassay panel
HAMBURG, GERMANY; HELSINKI, FINLAND – July 2, 2013. IBL International GmbH (“IBL International”) has obtained the exclusive right to distribute the GastroPanel®, a panel that consists of 4 immunoassays, from Biohit Oyj (“Biohit”) in Germany
IBL International obtains exclusive distribution rights for Sanquin’s immune reagent product portfolio in the Benelux
HAMBURG, GERMANY; Amsterdam, the Netherlands – 2 May 2013. IBL International GmbH (“IBL International”) has obtained the exclusive right to distribute the immune reagents portfolio of the division Reagents of Sanquin Blood Supply Foundation (“Sanquin”), Amsterdam, the Netherlands, in the Benelux. These immune reagents include
IBL International and UmanDiagnostics sign exclusive distribution agreement for NF-Light® Neurofilament ELISA for clinical research in neurodegeneration
HAMBURG, GERMANY; UMEA, SWEDEN – January 22, 2013. IBL International GmbH has obtained the exclusive right to distribute the NF-light® Neurofilament ELISA from UmanDiagnostics AB, Umea, Sweden in Europe outside Denmark, Norway and Sweden. IBL International will also distribute the NF-light® Neurofilament ELISA in the rest of the world on a non-exclusive basis.
Blood-based immunoassay for the diagnosis of Alzheimer’s disease
IBL International and the LVR-clinics at the Essen University Hospital of the University Duisburg-Essen will cooperate on the development of a blood-based immunoassay for the diagnosis of Alzheimer’s disease
IBL International and its partners in the Neruoallianz Consortium receive additional EUR 15 million funding
Rheinische Friedrich-Wilhelms-Universität Bonn, Universitätsklinikum Bonn, LVR-Klinikum Essen/Universitätsklinikum Essen, Research Center Jülich GmbH, Fraunhofer Institute SCAI UCB Pharma GmbH, IBL International GmbH and Life&Brain GmbH form the Neuroallianz Consortium, which has been rewarded.
IBL International will develop Amyloid assays for Alzheimer’s disease in cooperation with IBL Japan
HAMBURG, GERMANY; FUJIOKA, JAPAN – July 19th, 2012. IBL International GmbH (“IBL International”) has obtained the exclusive right to develop Amyloid-β ELISAs with particular combination of antibodies from Immuno Biological
IBL releases ASCO abstract with clinical data confirming the prognostic value of pTIMP-1 for overall survival in colorectal cancer
IBL International has announced today’s presentation at the American Society of Clinical Oncology of data on the prognostic impact of preoperative plasma tissue inhibitor of metalloproteinase 1 (pTIMP-1)
IBL International and Leiden University Medical Centre sign exclusive licence agreement for innovative Myasthenia gravis diagnostics
IBL International, a leader in the development, production and distribution of immunodiagnostic products, announced today that it has obtained an exclusive, worldwide licence from Leiden University
IBL International signs agreement for the exclusive distribution in Germany of Euro Diagnostica’s RIA products
Today the German company IBL International GmbH announced that it has signed an
IBL International and Universitätsklinikum Erlangen sign research agreement for evaluation of Alzheimer biomarkers
Today the German company IBL International announced that it has signed a research collaboration agreement with the group of Prof. Dr. Piotr Lewczuk from the Department of Psychiatry and
IBL International and TIMPCO sign exclusive worldwide license agreement for TIMP-1 as biomarker for colorectal cancer
Hamburg, September 30th, 2011. Today the German company IBL International announced that IBL has obtained the exclusive, worldwide license for the prognostic and predictive use of TIMP-1 as biomarker for colorectal and other
HMGBiotech and IBL International sign exclusive distribution agreement for HMGBiotech's HMGB research product line
Milano, Hamburg, January 1, 2011. Today the German company IBL International and the Italian company HMGBiotech Srl announced that IBL will exclusively distribute HMGBiotech’s HMGB protein research products worldwide. The
IBL International appoints Vice president Sales & Operations for its US operations
Deventer, 20 December 2010. Today IBL International announced the appointment of Dr. Bert Top as Vice President Sales & Operations for its US subsidiary, IBL International Corp.
Dr. Bert Top (48) brings 16 years of
IQ Products and IBL International close deal on distribution/marketing of diagnostic products in Germany
Groningen, Hamburg, May 1 2010. Today the German company IBL International, and the Dutch company IQ Products, announced an exclusive cooperation for the German diagnostics market. IBL will distribute and market IQ’s products in
IBL-International is expanding the autoantibody product line.
We have added products for the serology of celiac disease [the complete Newsletter]
Furthermore we are now offering the ultimate anti-CCP ELISA for the serological diagnosis of Rheumatoid Athritis [the complete Newsletter]
IBL International and Mediphos B.V. sign an exclusive distribution agreement
Effective October 1st 2009 Mediphos will exclusively distribute all IBL products in The Netherlands.
Mediphos Medical Supplies B.V. is a dynamic and flexible company, specialised in importing, marketing and distributing of...
2nd HMGB1 symposium - Sept. 25, 2009
IBL International and Shino-Test Corp., Japan have organized the 2nd HMGB1 symposium on September 25th, 2009 in Hamburg. This exciting event on one of the most interesting body proteins currently investigated is completely...
IBL International appoints Wim van Hulsenbeek and Jan Groen as members of the supervisory board
IBL International Holding B.V. today announced the appointment of Wim van Hulsenbeek as chairman and Jan Groen as member of the Supervisory Board.
Wim van Hulsenbeek was partner of KPMG for 25 years and was member of its Board...
IBL International announces the relaunch of its webpage
Today IBL International's website has been relaunched in its new design. This procedure now represents the new company IBL International much better after the acquisition by IBL International Holding B.V.
Meddens Diagnostics closes acquisition of IBL Hamburg to form IBL International
Hamburg and Deventer - Meddens Diagnostics B.V. (Deventer, The Netherlands) announced today it has closed the transaction to purchase all assets of IBL GmbH. Meddens Diagnostics has changed its name into IBL International and...
2nd International Symposium on Pheochromocytoma
IBL will take place at the 2nd International Symposium on Pheochromocytoma held from 17th – 20th September 2008 at Queens` College, Cambridge, UK. The symposium will present latest scientific discoveries and advances in genetics,...
1 st HMGB1 Symposium
1.st international HMGB1 symposium
HMGB1 has raised an enormous scientific interest since the beginning of this decade.HMGB1 seems to play an major role in many medical fields.
Now IBL and Shino-Test have organized the 1.st...
NON-EXTRACTION MELATONIN SALIVA ELISA
Measurement of melatonin in saliva has gained increasing interest during last years (literature: Pandi-Perumal et al. 2007).New studies have revealed that melatonin levels in saliva may represent a robust and reliable alternative...